LL-37: antimicrobial-peptide research without hype
A guide to distinguishing antimicrobial mechanism research from clinical safety or treatment claims.
Educational information only — not medical advice. This page does not diagnose conditions, recommend treatment, or replace care from a qualified clinician. The Peptide Center uses an evidence-first editorial process: regulatory sources, trial registries, and peer-reviewed research take priority; uncertainty is stated rather than filled with promises.
LL-37 is an endogenous antimicrobial peptide studied for its role in innate immunity and host defense. Antimicrobial activity in a laboratory model is not a clinical recommendation. Infection-related claims are particularly high stakes because delayed or inappropriate care can cause serious harm.
External sources and citations
- Therapeutic peptides: recent advances in discovery, synthesis, and clinical applications. Signal Transduction and Targeted Therapy, 2022
- ClinicalTrials.gov: Learn about studies
- FDA: The drug development process
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.
Alpha-Klotho mAb
An evidence-first reference for reading claims and source material about Alpha-Klotho mAb.
Open resourcePeptide briefEpithalon
An evidence-first reference for reading claims and source material about Epithalon.
Open resourcePeptide briefFLGR242
An evidence-first reference for reading claims and source material about FLGR242.
Open resourcePeptide briefFOXO4-DRI
An evidence-first reference for reading claims and source material about FOXO4-DRI.
Open resourcePeptide briefGonadorelin
An evidence-first reference for reading claims and source material about Gonadorelin.
Open resourcePeptide briefKisspeptin
An evidence-first reference for reading claims and source material about Kisspeptin.
Open resourceArticlePreparing for a peptide conversation with a clinician
A neutral question list for discussing goals, evidence, product status, and uncertainty.
Open resourceArticleAn adverse-event report is a safety signal, not proof of cause
How to read safety reporting responsibly—and why suspected problems should still be taken seriously.
Open resource